Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update
- PMID: 37042243
- PMCID: PMC10917144
- DOI: 10.1017/ice.2023.18
Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update
Conflict of interest statement
The following associations have been disclosed by the authors: L.K.K. reports a research grant from Merck; R.C. reports an advisory role with Moderna, Novavax, and Pfizer (consultant, speakers bureau, research contract), and Sanofi (speakers bureau). C.J.D. reports a research grant from Clorox and Ecolab. G.D. reports a research grant from Pfizer. V.G.L. reports a consultant role with Ferring; DJW reported an advisory role for Merck, Pfizer, PDI, Wellair, GAMA, and Germitec, and serving as a data safety monitoring board member at GSK. E.R.D. reports an advisory role with Merck, Pfizer, Seres, Ferring, Abbott, Summit, GSK, and research grants from Pfizer, Theriva Biologics, and Ferring. All other authors report no conflicts of interest related to this article.
References
-
- Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium difficile infections in acute-care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35 suppl 2:S48–S65. - PubMed
-
- The Society for Healthcare Epidemiology of America (SHEA) Handbook for SHEA-Sponsored Guidelines and Expert Guidance Documents. SHEA website. https://shea-online.org/wp-content/uploads/2022/02/2022-Handbook-Update-.... Accessed August 2021.
-
- Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention; website. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re.... Accessed February 20, 2023.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources